Novozymes A/S B

Novozymes is a biotechnology company based in Denmark. Co.'s business operations are centered on the development of industrial enzymes, microorganisms, and biopharmaceutical ingredients. Co. provides business-to-business biological solutions used in the production of numerous products such as biofuel, detergents, feed, and crops. Co.'s business operations are organized along two segments: the Enzyme Business which is divided into four areas, providing industrial enzymes for household care, food & beverages, bioenergy, and feed & other technical; and the BioBusiness which is home to Co.'s microorganisms and biopharmaceutical ingredients.
  • TickerNZYM B
  • ISINDK0060336014
  • ExchangeNasdaq Nordic Copenhagen
  • SectorPharmaceuticals & Biotechnology
  • CountryDenmark

Analysts

Eivind Sars Veddeng ...
  • Jimi Lehtonen
  • Jon Masdal
  • Martin Arnell
  • Martin Huseby Karlsen
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

An unfavourable environment weighs on NOVOZYMES A/S, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of NOVOZYMES A/S (DK), active in the Specialty Chemicals industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date July 9, 2019, the closing price was DKK 307.00 and its target price was estimated at DKK 275.43.

Rune Majlund Dahl

Novozymes (Sell, TP: DKK230.00) - Strategy requires cultural change

Yesterday Novozymes hosted a CMD outlining new long-term targets i.e. 5%+ annual organic growth for the period with 2020e likely to be hit by portfolio changes; and an EBIT margin of 28% or above by 2022e, which represents downside risk to consensus. The new strategy is a shift from idealistic R&D to greater focus on commercial execution to fuel higher growth; but will take time. We retain our SELL and DKK230 target price.

Rob Hales

Morningstar | Disappointing 1Q for Novozymes Due to Floods in Midwest U.S.; Guidance Trimmed

Wide-moat Novozymes reported a disappointing first quarter with negative 4% organic growth. The company guided for negative growth in the first quarter, but growth in Bioenergy was worse than expected due to flooding in the U.S. Midwest, which took a major toll on customers. Volume lost is not expected to be fully recovered during the year. Consequently, Novozymes trimmed the top end of its 2019 organic growth guidance to 3%-5% from 3%-6%. We were already conservative on the year with our expectation for 3.8% organic growth, so we don’t expect to make any major changes to our forecast or our D...

Rob Hales

Disappointing 1Q for Novozymes Due to Floods in Midwest U.S.; Guidance Trimmed

Wide-moat Novozymes reported a disappointing first quarter with negative 4% organic growth. The company guided for negative growth in the first quarter, but growth in Bioenergy was worse than expected due to flooding in the U.S. Midwest, which took a major toll on customers. Volume lost is not expected to be fully recovered during the year. Consequently, Novozymes trimmed the top end of its 2019 organic growth guidance to 3%-5% from 3%-6%. We were already conservative on the year with our expect...

Rune Majlund Dahl

Novozymes (Sell, TP: DKK230.00) - All key divisions disappoint

Novozymes (NZYMB DC, Sell) - All key divisions disappoint (10 pages)

Rune Majlund Dahl

Novozymes (Sell, TP: DKK230.00) - Awaiting the strategy review

We forecast Q1 organic growth of -1.0% (results due at 08:00 CET on 24 April), as key divisions including Household Care and Agriculture & Feed continue to struggle and are set for a back-end loaded 2019. We expect an EBIT margin of 28.4% (-0.5%-points YOY). The changes to our 2019 forecasts reflect positive FX and higher deferred income from the terminated Bayer deal. We reiterate our SELL and DKK230 target price.

1 director sold

A director at Novozymes A S sold 765,000 shares at 302.390DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boa...

Eivind Sars Veddeng ...
  • Jimi Lehtonen
  • Jon Masdal
  • Martin Arnell
  • Martin Huseby Karlsen
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

Jesper Ingildsen ...
  • Joachim Gunell
  • Mattias Holmberg
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling
  • Rune Majlund Dahl

Northern Lights

Alexander Aukner ...
  • Eivind Sars Veddeng
  • Håkon Astrup
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Simen Mortensen

Northern Lights

Alexander Aukner ...
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Paul Harper
  • Rune Majlund Dahl

Northern Lights

Christer Magnergård ...
  • Christoffer Wang Bjørnsen
  • Eivind Sars Veddeng
  • Joachim Gunell
  • Jon Masdal
  • Martin Arnell
  • Martin Hoang Nguyen
  • Mattias Holmberg
  • Nicolay Dyvik
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Simen Mortensen

Northern Lights

An unfavourable environment weighs on NOVOZYMES A/S, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of NOVOZYMES A/S (DK), active in the Specialty Chemicals industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date July 9, 2019, the closing price was DKK 307.00 and its target price was estimated at DKK 275.43.

Nurhayati Wan

Novozymes

Nurhayati Wan

Novozymes

Nurhayati Wan

Novozymes

Nurhayati Wan

Novozymes

MarketLine Department

Royal DSM N.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Royal DSM N.V. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Royal DSM N.V. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highl...

Novozymes – Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Expert Corporate Governance Service (ECGS)

Novozymes - February 27, 2019

In general, Novozymes is in compliance with the Danish regulations relating to the organisation and procedures of the Annual General Meeting. Under ITEM 5a, it is proposed to re-appoint Mr. Jorgen Buhl Rasmussen as Chairman of the board of directors. Although he is considered independent, ECGS notes that Mr. Buhl Rasmussen is currently chairing Novozymes' remuneration committee, which is not in accordance with its guidelines. As a consequence, ECGS normally would have recommended opposition. However, considering that the proxy card does not permit this, it recommends abstention instead. Unde...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch